Advisor Group Holdings, Inc. Clovis Oncology, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $248 - $675	237 Added 0.62%	38,505 $45,000
Q2 2022 Aug 10, 2022	BUY	$0.63 - $2.96 $279 - $1,314	444 Added 1.17%	38,268 $102,000
Q1 2022 May 04, 2022	SELL	$1.43 - $3.14 $6,786 - $14,902	-4,746 Reduced 11.15%	37,824 $14,000
Q3 2021 Nov 05, 2021	BUY	$4.06 - $5.8 $17,985 - $25,694	4,430 Added 11.62%	42,570 $189,000
Q2 2021 Aug 02, 2021	BUY	$5.02 - $7.05 $21,816 - $30,639	4,346 Added 12.86%	38,140 $221,000
Q1 2021 May 13, 2021	BUY	$4.81 - $10.34 $29,956 - $64,397	6,228 Added 22.59%	33,794 $239,000
Q4 2020 Feb 10, 2021	SELL	$4.13 - $6.41 $90,603 - $140,622	-21,938 Reduced 44.32%	27,566 $132,000
Q3 2020 Nov 12, 2020	BUY	$4.82 - $7.72 $55,661 - $89,150	11,548 Added 30.42%	49,504 $304,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $53,719 - $91,483	9,441 Added 33.11%	37,956 $255,000
Q1 2020 May 18, 2020	BUY	$3.77 - $11.0 $107,501 - $313,665	28,515 New	28,515 $188,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.